Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), filed a Form 4 on November 4, 2026, disclosing the sale of 4,769 shares of common stock in two transactions executed under a Rule 10b5-1 trading plan.
Key Highlights
- First sale: 3,300 shares disposed of on November 4, 2026, at a weighted average price of $15.3824, with individual sale prices ranging from $14.91 to $15.89.
- Second sale: 1,469 shares disposed of on November 4, 2026, at a weighted average price of $16.2018, with individual sale prices ranging from $15.91 to $16.78.
- Remaining holdings: Following both transactions, van Houte directly beneficially owned 42,745 shares of common stock.
- 10b5-1 plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
- Signing authority: The form was signed by Daniel Burbach as Attorney-in-Fact for Hans van Houte on November 4, 2026.
Nurix Therapeutics CFO Discloses Two Planned Share Sales on November 4, 2026
According to the Form 4 filed with the SEC, Hans van Houte, identified as Chief Financial Officer of Nurix Therapeutics, Inc., reported two disposals of common stock on November 4, 2026, both coded as sales ("S") under a previously adopted Rule 10b5-1 trading plan. The filing notes that the transactions were non-derivative and directly held.
In the first transaction, the filing discloses that 3,300 shares were sold at a weighted average price of $15.3824 per share, with the lowest sale price in that tranche at $14.91 and the highest at $15.89. Following this disposal, van Houte's direct beneficial ownership stood at 44,214 shares. The second transaction involved the sale of 1,469 shares at a weighted average price of $16.2018, with prices ranging from $15.91 to $16.78 per share, reducing his direct holdings to 42,745 shares.
The filing states that van Houte undertakes to provide full information regarding the total number of shares sold at each separate price within the stated ranges upon request to the SEC staff, the issuer, or its stockholders. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing reports two open-market sales of Nurix Therapeutics common stock by CFO Hans van Houte on November 4, 2026, totaling 4,769 shares sold under a pre-established Rule 10b5-1 plan, leaving him with 42,745 directly held shares.




Please wait processing your request...